Sign inJoin waitlistJoin the waitlist

Zoe Quandt

Clinical Lead for Adults Eligible for Teplizumab · UCSF

Credentials: · · · · · ·

History

UCSF
Present
University of California, San Francisco
Present
Stanford Health Care
Present

Endocrinology, Diabetes, and Metabolism
University of California (San Francisco) School of Medicine
2016–2018
Internal Medicine
Stanford Health Care
2013–2016
University of California, San Francisco School of Medicine
2009–2013
Resident
Stanford Health Care

Research

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Review · Diabetes · 2018 · 489 citations
Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes
Review · Clinical & Experimental Immunology · 2020 · First of 3 authors · 143 citations
The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy
Review · Cancer Immunology Research · 2018 · 135 citations

Kevan Herold
8 papers
Elad Ziv
6 papers
Christine Lovly
5 papers
ES
Elad Sharon
5 papers
Matthew Gubens
5 papers
Melissa Lechner
5 papers
AS
Adam Schoenfeld
4 papers · 1 as a fellow
Douglas Johnson
4 papers
Michail Lionakis
4 papers
Rohit Thummalapalli
4 papers
Sam Brondfield
4 papers
Sara Vazquez
4 papers

Grants

Leveraging JAK Inhibitors to Halt Autoimmune Attack Induced by Immune Checkpoint Inhibitors
National Institute of Allergy and Infectious Diseases · U01
PI · $1.2M · University of California Los Angeles
2026–2031
Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes: Immunological Mechanisms and Biomarker Discovery in Provoked Beta Cell Autoimmunity
National Institute of Allergy and Infectious Diseases · K08
Contact PI · $401.3K · University of California, San Francisco
2025–2030